150(top 1%)
PR articles
38.2K(top 0.1%)
PR citations
65(top 1%)
PR h-index
67(top 1%)
h-index
169
documents
47.2K
doc citations
3.1K
citing journals
100
times ranked

Publications

159 peer-reviewed articles • 43,110 peer-reviewed citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Spatial–Temporal Diversity of Extrachromosomal DNA Shapes Urothelial Carcinoma Evolution and the Tumor Immune Microenvironment
Cancer Discovery, 2025, 15, 1225-1246
6.823Citations (PDF)
2Energetics of whole genome doubling and genomic instability
Cancer Letters, 2025, 630, 217878
6.70Citations (PDF)
3Selective Depletion of Cancer Cells with Extrachromosomal DNA via Lentiviral Infection
Cancer Research Communications, 2025, 5, 1458-1465
2.11Citations (PDF)
4The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen
Cancer Research, 2024, 84, 741-756
4.260Citations (PDF)
513. AmpliconSuite: Analyzing focal amplifications in cancer genomes
Cancer Genetics, 2024, 286-287, S5
1.81Citations (PDF)
6Mapping extrachromosomal DNA amplifications during cancer progression
Nature Genetics, 2024, 56, 2447-2454
14.166Citations (PDF)
7Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network
Cancer Epidemiology Biomarkers and Prevention, 2023, 32, 487-495
0.612Citations (PDF)
8Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
Cancer Immunology Research, 2023, 11, 629-645
3.119Citations (PDF)
9Extrachromosomal DNA in the cancerous transformation of Barrett’s oesophagus
Nature, 2023, 616, 798-805
31.3176Citations (PDF)
10Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas
Neuro-Oncology, 2023, 25, 1721-1723
0.956Citations (PDF)
11[ 18 F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial
BMJ Open, 2023, 13, e071327
1.223Citations (PDF)
12EPCO-37. DISSECTING GBM EVOLUTION FOLLOWING STANDARD-OF-CARE BY LARGE-SCALE LONGITUDINAL SINGLE NUCLEUS RNA-SEQUENCING
Neuro-Oncology, 2023, 25, v132-v132
0.91Citations (PDF)
13DISP-10. ENHANCING TRUST AND REPRESENTATIVE PARTICIPATION IN THE INTERNATIONAL LOW GRADE GLIOMA REGISTRY: COMMUNITY ENGAGEMENT STRATEGIES AND RECOMMENDATIONS
Neuro-Oncology, 2023, 25, v138-v139
0.90Citations (PDF)
14DISP-04. EXPLORING ENGAGEMENT IN LOW GRADE GLIOMA GENOMIC RESEARCH: A COMPARATIVE ANALYSIS OF THREE APPROACHES
Neuro-Oncology, 2023, 25, v137-v137
0.90Citations (PDF)
15Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort
Neuro-Oncology Advances, 2023, 5,
0.77Citations (PDF)
16QOL-09. QUALITY OF LIFE AFTER SURGERY FOR LOWER GRADE GLIOMAS
Neuro-Oncology, 2023, 25, v250-v250
0.90Citations (PDF)
17EPCO-34. IMAGE-BASED PHENOTYPIC HIGH-CONTENT CRISPR-CAS9 SCREEN FOR CHARACTERIZING CANCER DRIVERS IN PEDIATRIC HIGH-GRADE GLIOMA
Neuro-Oncology, 2023, 25, v131-v131
0.90Citations (PDF)
18EPCO-09. CHARACTERIZING THE GBM CELLULAR LANDSCAPE BY LARGE-SCALE SINGLE-NUCLEUS RNA-SEQUENCING
Neuro-Oncology, 2023, 25, v125-v125
0.91Citations (PDF)
19CTNI-23. SINGLE CELL TRANSCRIPTOMICS, PHARMACOKINETICS, AND PHARMACODYNAMICS OF COMBINED CDK4/6 AND MTOR INHIBITION IN A PHASE 0 TRIAL OF RECURRENT HIGH-GRADE GLIOMA
Neuro-Oncology, 2023, 25, v78-v79
0.92Citations (PDF)
20Live-Cell Imaging Shows Uneven Segregation of Extrachromosomal DNA Elements and Transcriptionally Active Extrachromosomal DNA Hubs in Cancer
Cancer Discovery, 2022, 12, 468-483
6.8170Citations (PDF)
21Spatiotemporal dynamics of clonal selection and diversification in normal endometrial epithelium
Nature Communications, 2022, 13,
11.052Citations (PDF)
22Glioma progression is shaped by genetic evolution and microenvironment interactions
Cell, 2022, 185, 2184-2199.e16
23.8468Citations (PDF)
23Extrachromosomal DNA amplifications in cancer
Nature Reviews Genetics, 2022, 23, 760-771
29.1129Citations (PDF)
24Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma
Cancer Discovery, 2022, 12, 2820-2837
6.8119Citations (PDF)
25Lineage-coupled clonal capture identifies clonal evolution mechanisms and vulnerabilities of BRAFV600E inhibition resistance in melanoma
Cell Discovery, 2022, 8,
6.59Citations (PDF)
26Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
Nature Communications, 2021, 12,
11.0123Citations (PDF)
27Perspective of mesenchymal transformation in glioblastoma
Acta Neuropathologica Communications, 2021, 9,
3.4140Citations (PDF)
28Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer
Nature Genetics, 2021, 53, 1088-1096
14.1153Citations (PDF)
29Spatial concordance of DNA methylation classification in diffuse glioma
Neuro-Oncology, 2021, 23, 2054-2065
0.934Citations (PDF)
30Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription
Cancer Cell, 2021, 39, 694-707.e7
28.7270Citations (PDF)
31Serum cell-free DNA epigenetic biomarkers aid glioma diagnostics and monitoring
Neuro-Oncology, 2021, 23, 1423-1424
0.99Citations (PDF)
32Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine
Nature Communications, 2021, 12,
11.053Citations (PDF)
33Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response
Nature Genetics, 2021, 53, 1456-1468
14.1264Citations (PDF)
34A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram
Neuro-Oncology Advances, 2021, 3,
0.712Citations (PDF)
35INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY
Neuro-Oncology, 2021, 23, vi106-vi107
0.91Citations (PDF)
36TMOD-13. IDENTIFYING DRIVERS IN THE CONVERGING SYNTENIC REGIONS OF SPONTANEOUS CANINE AND PEDIATRIC HIGH-GRADE GLIOMA USING IMAGING BASED CRISPR-CAS9 ARRAY SCREEN
Neuro-Oncology, 2021, 23, vi218-vi218
0.90Citations (PDF)
37LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study
BMJ Open, 2021, 11, e054075
1.26Citations (PDF)
38EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma
Clinical Cancer Research, 2020, 26, 1395-1407
4.553Citations (PDF)
39Molecular and clonal evolution in recurrent metastatic gliosarcoma
Journal of Physical Education and Sports Management, 2020, 6, a004671
0.812Citations (PDF)
40Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure
Nature Genetics, 2020, 52, 1178-1188
14.1121Citations (PDF)
41MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas
Nature Communications, 2020, 11,
11.0184Citations (PDF)
42Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma
Genome Biology, 2020, 21,
4.8104Citations (PDF)
43Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers
Nature Genetics, 2020, 52, 891-897
14.1568Citations (PDF)
44A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
Nature Communications, 2020, 11,
11.093Citations (PDF)
45iGLASS: imaging integration into the Glioma Longitudinal Analysis Consortium
Neuro-Oncology, 2020, 22, 1545-1546
0.919Citations (PDF)
46Comparative Molecular Life History of Spontaneous Canine and Human Gliomas
Cancer Cell, 2020, 37, 243-257.e7
28.7108Citations (PDF)
47Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma
Clinical Cancer Research, 2020, 26, 1094-1104
4.5234Citations (PDF)
48Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer
Nature Genetics, 2020, 52, 294-305
14.1274Citations (PDF)
49Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Neuro-Oncology, 2020, 22, 1073-1113
0.91,096Citations (PDF)
50EPCO-27. GLIOMA SINGLE CELL MULTI-OMIC ANALYSES REVEALS REGULATORS OF PLASTICITY AND ADAPTIVE STRESS RESPONSE
Neuro-Oncology, 2020, 22, ii75-ii75
0.90Citations (PDF)
51EPCO-11. IN VIVO FUNCTIONAL GENOMIC SCREEN IDENTIFIES WISP1 AS AN OVEREXPRESSED DRIVER OF GLIOBLASTOMA
Neuro-Oncology, 2020, 22, ii71-ii71
0.90Citations (PDF)
52TMOD-13. RESEARCH RESOURCES FOR OLIGODENDROGLIOMA NOW AVAILABLE TO RESEARCH COMMUNITY
Neuro-Oncology, 2020, 22, ii230-ii230
0.90Citations (PDF)
53EPCO-29. EPIGENOMICS OF THE GLIOMA LONGITUDINAL ANALYSIS (GLASS) CONSORTIUM
Neuro-Oncology, 2020, 22, ii75-ii75
0.90Citations (PDF)
54EPCO-15. TUMOR TREATMENT WITH IONIZING RADIATION IS ASSOCIATED WITH A CLINICALLY RELEVANT DELETION SIGNATURE
Neuro-Oncology, 2020, 22, ii72-ii72
0.90Citations (PDF)
55EPCO-08. TUMOR-IMMUNE INTERACTIONS ARE DYNAMIC AND INFLUENCE THE EVOLUTIONARY TRAJECTORY OF ADULT DIFFUSE GLIOMA
Neuro-Oncology, 2020, 22, ii70-ii71
0.90Citations (PDF)
56BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma
Scientific Reports, 2019, 9,
2.789Citations (PDF)
57Extrachromosomal oncogene amplification in tumour pathogenesis and evolution
Nature Reviews Cancer, 2019, 19, 283-288
33.8324Citations (PDF)
58Prospective Clinical Sequencing of Adult Glioma
Molecular Cancer Therapeutics, 2019, 18, 991-1000
1.318Citations (PDF)
59PATH-48. THE DNA METHYLATION LANDSCAPE OF CORE AND PERIPHERAL DIFFUSE GLIOMA REGIONS SHOWS LITTLE SPATIAL SUBTYPE HETEROGENEITY AFTER CONSIDERING TUMOR PURITY
Neuro-Oncology, 2019, 21, vi154-vi154
0.90Citations (PDF)
60COMP-15. MOLECULAR AND CLONAL EVOLUTION IN RECURRENT METASTATIC GLIOSARCOMA
Neuro-Oncology, 2019, 21, vi64-vi64
0.90Citations (PDF)
61EPID-23. PURSUIT OF AN INTERNATIONAL LANGUAGE OF GLIOMA RESEARCH: COMMON DATA ELEMENTS FOR THE LONGITUDINAL STUDY OF ADULT MALIGNANT GLIOMA
Neuro-Oncology, 2019, 21, vi79-vi79
0.92Citations (PDF)
62GENE-40. CHARACTERIZING EPIGENETIC INTRATUMORAL HETEROGENEITY IN GLIOMA USING SINGLE-CELL BISULFITE SEQUENCING
Neuro-Oncology, 2019, 21, vi106-vi106
0.90Citations (PDF)
63GENE-57. COMPARATIVE MOLECULAR LIFE HISTORY OF SPONTANEOUS CANINE AND HUMAN GLIOMA
Neuro-Oncology, 2019, 21, vi110-vi110
0.90Citations (PDF)
64GENE-28. LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS
Neuro-Oncology, 2019, 21, vi103-vi103
0.93Citations (PDF)
65Circular ecDNA promotes accessible chromatin and high oncogene expression
Nature, 2019, 575, 699-703
31.3639Citations (PDF)
66Longitudinal molecular trajectories of diffuse glioma in adults
Nature, 2019, 576, 112-120
31.3528Citations (PDF)
67Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target
Journal of Clinical Investigation, 2019, 129, 137-149
6.8376Citations (PDF)
68Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma
Nature Genetics, 2018, 50, 708-717
14.1312Citations (PDF)
69Reconstructing the molecular life history of gliomas
Acta Neuropathologica, 2018, 135, 649-670
5.882Citations (PDF)
70Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium
Neuro-Oncology, 2018, 20, 873-884
0.9192Citations (PDF)
71Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions
Oncogenesis, 2018, 7,
3.353Citations (PDF)
72TumorFusions: an integrative resource for cancer-associated transcript fusions
Nucleic Acids Research, 2018, 46, D1144-D1149
11.2232Citations (PDF)
73EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
Neuro-Oncology, 2018, 20, 743-752
0.9279Citations (PDF)
74DDIS-03. EGFR AMPLIFICATION INDUCED INCREASED DNA DAMAGE RESPONSE AND PREDICTED SELECTIVE SENSITIVITY TO TALAZOPARIB (PARP INHIBITOR) IN GLIOBLASTOMA STEM-LIKE CELLS
Neuro-Oncology, 2018, 20, vi69-vi69
0.90Citations (PDF)
75COMP-07. COMPARATIVE MOLECULAR LIFE HISTORY OF SPONTANEOUS CANINE AND HUMAN GLIOMA
Neuro-Oncology, 2018, 20, vi64-vi65
0.93Citations (PDF)
76IMMU-36. IMMUNE RESPONSES IN CANINE GLIOMAS ARE ENRICHED AT THE INFILTRATING EDGE OF ASTROCYTOMAS
Neuro-Oncology, 2018, 20, vi129-vi129
0.90Citations (PDF)
77TMOD-18. THE PATIENT DERIVED XENOGRAFT NATIONAL RESOURCE: A COMPREHENSIVE COLLECTION OF HIGH-GRADE GLIOMA MODELS FOR PRE-CLINICAL AND TRANSLATIONAL STUDIES
Neuro-Oncology, 2018, 20, vi272-vi272
0.90Citations (PDF)
78DRES-05. MOLECULAR EVOLUTION OF DIFFUSE GLIOMAS AND THE GLIOMA LONGITUDINAL ANALYSIS CONSORTIUM
Neuro-Oncology, 2018, 20, vi76-vi76
0.90Citations (PDF)
79RBTT-07. NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS
Neuro-Oncology, 2018, 20, vi235-vi235
0.91Citations (PDF)
80Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy
Nature Genetics, 2018, 50, 1399-1411
14.1193Citations (PDF)
81Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults
Neurologic Clinics, 2018, 36, 421-437
1.913Citations (PDF)
82The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations
Cancer Cell, 2018, 34, 197-210.e5
28.7180Citations (PDF)
83Systematic analysis of telomere length and somatic alterations in 31 cancer types
Nature Genetics, 2017, 49, 349-357
14.1614Citations (PDF)
84Glioma: experimental models and reality
Acta Neuropathologica, 2017, 133, 263-282
5.8271Citations (PDF)
85Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma
Molecular Cancer Research, 2017, 15, 532-540
2.629Citations (PDF)
86Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer
Cancer Research, 2017, 77, 3502-3512
4.241Citations (PDF)
87Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma
Neuro-Oncology, 2017, 19, 786-795
0.9105Citations (PDF)
88PAF promotes stemness and radioresistance of glioma stem cells
Proceedings of the National Academy of Sciences of the United States of America, 2017, 114,
5.353Citations (PDF)
89Exosomes from Glioma-Associated Mesenchymal Stem Cells Increase the Tumorigenicity of Glioma Stem-like Cells via Transfer of miR-1587
Cancer Research, 2017, 77, 5808-5819
4.2203Citations (PDF)
90Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
Cancer Cell, 2017, 32, 204-220.e15
28.7848Citations (PDF)
91Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas
Cell, 2017, 171, 950-965.e28
23.81,020Citations (PDF)
92Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment
Cancer Cell, 2017, 32, 42-56.e6
28.71,819Citations (PDF)
93GlioVis data portal for visualization and analysis of brain tumor expression datasets
Neuro-Oncology, 2017, 19, 139-141
0.9850Citations (PDF)
94CSIG-16. DEPLETION OF CLK2 SENSITIZES GLIOMA CELLS TO PI3K/mTOR AND FGFR INHIBITION
Neuro-Oncology, 2016, 18, vi44-vi44
0.90Citations (PDF)
95TMOD-31. AN INFLAMMATION RESPONSE GENE SIGNATURE IS ASSOCIATED WITH PROGNOSIS OF GLIOMA PATIENTS WITH 1p/19q CO-DELETION TUMORS
Neuro-Oncology, 2016, 18, vi213-vi213
0.90Citations (PDF)
96TMOD-36. GENE EXPRESSION ANALYSIS OF SHORT AND LONG SURVIVAL GROUPS OF GLIOBLASTOMA PATIENT-DERIVED ORTHOTOPIC XENOGRAFTS
Neuro-Oncology, 2016, 18, vi214-vi214
0.90Citations (PDF)
97Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies
Neuro-Oncology, 2016, 18, 1357-1366
0.9132Citations (PDF)
98Longitudinal genomic characterization of brain tumors for identification of therapeutic vulnerabilities: Table 1.
Neuro-Oncology, 2016, 18, 1037-1039
0.910Citations (PDF)
99MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma
Molecular Cancer Therapeutics, 2016, 15, 1656-1668
1.328Citations (PDF)
100Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma
Cancer Cell, 2016, 29, 723-736
28.7611Citations (PDF)
101Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Nature Genetics, 2016, 48, 607-616
14.11,153Citations (PDF)
102Moving the needle: Optimizing classification for glioma
Science Translational Medicine, 2016, 8,
8.725Citations (PDF)
103TMIC-14. TUMOR EVOLUTION OF GLIOMA INTRINSIC GENE EXPRESSION SUBTYPE ASSOCIATES WITH IMMUNOLOGICAL CHANGES IN THE MICROENVIRONMENT
Neuro-Oncology, 2016, 18, vi202-vi202
0.911Citations (PDF)
104Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
Cell, 2016, 164, 550-563
23.82,109Citations (PDF)
105EPIG-14EPIGENOMIC (DNA METHYLATION AND EXPRESSION) SIGNATURES DEFINE SUBSETS OF BOTH IDHmut AND IDHwt GLIOMA WITH DISTINCT CLINICAL OUTCOMES
Neuro-Oncology, 2015, 17, v89.2-v89
0.90Citations (PDF)
106Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain
Acta Neuropathologica, 2015, 130, 419-434
5.885Citations (PDF)
107GENO-18A 35 GENES SIGNATURE FOR PREDICTING OUTCOME IN GLIOMA PATIENTS WITH 1p/19q CODEL
Neuro-Oncology, 2015, 17, v95.2-v95
0.90Citations (PDF)
108GENO-12CLONAL EVOLUTION AND GENOMIC DIVERSITY IN A PANEL GLIOBLASTOMA TUMORS, NEUROSPHERE CULTURES AND ORTHOTOPIC XENOGRAFTS
Neuro-Oncology, 2015, 17, v93.4-v94
0.90Citations (PDF)
109Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non‐sarcomatoid renal carcinomas
Journal of Pathology: Clinical Research, 2015, 1, 212-224
2.112Citations (PDF)
110GENO-36GLIOMA SPHERE-FORMING CELLS REVEAL INTRINSIC GLOBAL HYPERMETHYLATION ASSOCIATED WITH GBM RADIATION RESISTANCE
Neuro-Oncology, 2015, 17, v99.5-v100
0.90Citations (PDF)
111Mir-21–Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact
Journal of Neuroscience, 2015, 35, 15097-15112
2.358Citations (PDF)
112Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution
Genome Research, 2015, 25, 316-327
3.2403Citations (PDF)
113Toward understanding and exploiting tumor heterogeneity
Nature Medicine, 2015, 21, 846-853
22.8727Citations (PDF)
114Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
New England Journal of Medicine, 2015, 372, 2481-2498
19.43,087Citations (PDF)
115Ets Factors Regulate Neural Stem Cell Depletion and Gliogenesis in Ras Pathway Glioma
Cell Reports, 2015, 12, 258-271
4.463Citations (PDF)
116Novel kinase fusion transcripts found in endometrial cancer
Scientific Reports, 2015, 5,
2.713Citations (PDF)
117Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer
Journal of Clinical Investigation, 2015, 125, 4625-4637
6.873Citations (PDF)
118A High Notch Pathway Activation Predicts Response to γ Secretase Inhibitors in Proneural Subtype of Glioma Tumor-Initiating Cells
Stem Cells, 2014, 32, 301-312
2.7127Citations (PDF)
119PRADA: pipeline for RNA sequencing data analysis
Bioinformatics, 2014, 30, 2224-2226
3.2159Citations (PDF)
120GE-37 * INTEGRATED GENOMIC ANALYSIS OF LOW GRADE GLIOMA AND GLIOBLASTOMA REVEALS MOLECULAR STRATIFICATION BY IDH STATUS ACROSS GRADES AND HISTOLOGIES
Neuro-Oncology, 2014, 16, v104-v104
0.91Citations (PDF)
121Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation process
Proceedings of the National Academy of Sciences of the United States of America, 2014, 111,
5.3126Citations (PDF)
122ZFHX4 Interacts with the NuRD Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State
Cell Reports, 2014, 6, 313-324
4.4125Citations (PDF)
123GE-14 * TRANSCRIPTOMICPLASTICITYIS ASSOCIATED WITH THE TUMOR MICROENVIRONMENT IN GLIOBLASTOMA
Neuro-Oncology, 2014, 16, v99-v99
0.90Citations (PDF)
124Inferring tumour purity and stromal and immune cell admixture from expression data
Nature Communications, 2013, 4,
11.08,626Citations (PDF)
125The Somatic Genomic Landscape of Glioblastoma
Cell, 2013, 155, 462-477
23.84,886Citations (PDF)
126Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer
Nature Structural and Molecular Biology, 2013, 20, 908-913
5.9559Citations (PDF)
127Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target
Genes and Development, 2013, 27, 197-210
2.967Citations (PDF)
128A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival
Genes and Development, 2013, 27, 1462-1472
2.983Citations (PDF)
129Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
Journal of Clinical Investigation, 2013, ,
6.8490Citations (PDF)
130Predicting time to ovarian carcinoma recurrence using protein markers
Journal of Clinical Investigation, 2013, ,
6.848Citations (PDF)
131Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo
Clinical Cancer Research, 2012, 18, 5911-5923
4.575Citations (PDF)
132Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Nature, 2012, 483, 484-488
31.3713Citations (PDF)
133The cellular origin for malignant glioma and prospects for clinical advancements
Expert Review of Molecular Diagnostics, 2012, 12, 383-394
2.3200Citations (PDF)
134Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia
Blood, 2012, 119, 5071-5077
3.6175Citations (PDF)
135PathSeq: software to identify or discover microbes by deep sequencing of human tissue
Nature Biotechnology, 2011, 29, 393-396
20.2332Citations (PDF)
136Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
Nature Genetics, 2011, 43, 964-968
14.1286Citations (PDF)
137Mosaic Analysis with Double Markers Reveals Tumor Cell of Origin in Glioma
Cell, 2011, 146, 209-221
23.8669Citations (PDF)
138Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies
Cancer Research, 2011, 71, 7587-7596
4.276Citations (PDF)
139Unifying Gene Expression Measures from Multiple Platforms Using Factor Analysis
PLoS ONE, 2011, 6, e17691
1.514Citations (PDF)
140Suppression of lung adenocarcinoma progression by Nkx2-1
Nature, 2011, 473, 101-104
31.3457Citations (PDF)
141Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Cancer Cell, 2010, 17, 98-110
28.77,172Citations (PDF)
142Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Cancer Cell, 2010, 17, 510-522
28.72,266Citations (PDF)
143Integrative analysis of the melanoma transcriptome
Genome Research, 2010, 20, 413-427
3.2260Citations (PDF)
144SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
Nature Genetics, 2009, 41, 1238-1242
14.1933Citations (PDF)
145Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
Nature Medicine, 2008, 14, 822-827
22.81,100Citations (PDF)
146Differential Regulation of Foxo3a Target Genes in Erythropoiesis
Molecular and Cellular Biology, 2007, 27, 3839-3854
1.580Citations (PDF)
147Characterizing the cancer genome in lung adenocarcinoma
Nature, 2007, 450, 893-898
31.31,055Citations (PDF)
148A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia
Journal of Clinical Investigation, 2007, 117, 2611-2620
6.8112Citations (PDF)
149Essential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells
Nature Genetics, 2006, 38, 1269-1277
14.1174Citations (PDF)
150Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
New England Journal of Medicine, 2004, 350, 1617-1628
19.41,288Citations (PDF)
151Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Neuro-Oncology, 0, 27, 2751-2788
0.965Citations (PDF)
152Challenges in the return of molecular tumor profiling results
Journal of the National Cancer Institute, 0, 118, 776-782
3.40Citations (PDF)
153Single-nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a Phase 0/1 trial of recurrent high-grade glioma
Neuro-Oncology, 0, 28, 659-671
0.98Citations (PDF)
154DISP-22. Community perspectives on return of results and ownership of data and specimens in low-grade glioma genomic research
Neuro-Oncology, 0, 27, v198-v198
0.90Citations (PDF)
155Community perspectives on the return of research results and ownership of data and specimens for brain tumor genomic research
SSM Qualitative Research in Health, 0, 9, 100741
1.20Citations (PDF)
156DNA methylation profiling reveals a novel subtype harboring IDH mutation in H3-altered gliomas
Neuro-Oncology, 0, 28, 1502-1516
0.90Citations (PDF)
157Abstract B033: Epigenetic determinants of transcriptional cellular states in glioblastoma
Cancer Research, 0, 86, B033-B033
4.20Citations (PDF)
158Abstract 66: Gene co-amplification and structural patterns reveal principles of extrachromosomal DNA in cancer.
Cancer Research, 0, 86, 66-66
4.20Citations (PDF)
159Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?
Neuro-Oncology, 0, 28, 1829-1839
0.91Citations (PDF)